千亿创新药巨头，又出手并购

Group 1 - China Biologic Products announced the acquisition of 100% equity in Hejiya Biotech for 1.2 billion RMB, enhancing its position in the small RNA (siRNA) sector [1] - This acquisition follows a previous purchase of Lixin Pharmaceutical for approximately 3.5 billion RMB in July 2025, indicating a strategic focus on expanding its small RNA portfolio [1] - The stock price of China Biologic Products closed at 6.91 HKD per share, with a market capitalization of 129.6 billion RMB as of January 13 [1] Group 2 - Hejiya Biotech, established in 2018, specializes in innovative siRNA products with advantages in long-lasting effects and low dosages, boasting six delivery platforms and four innovative drugs in clinical stages [2] - Hejiya's Kylo-11, targeting LPA, is the first siRNA product to achieve "one injection per year" in clinical trials, marking a significant advancement in the treatment of hyperlipidemia [2] - The company has over 20 projects in preclinical stages, covering high-value areas such as cardiovascular, metabolic, and neurological diseases [2] Group 3 - The acquisition allows China Biologic Products to complete its innovative drug layout in the cardiovascular field and significantly expand into major chronic disease areas [3] - The chairman of China Biologic Products emphasized that Hejiya's differentiated delivery technology platform will enhance the company's core competitiveness in the small RNA sector [3] - Industry experts believe this acquisition represents a strategic alignment of technical capabilities and commercialization strengths, potentially accelerating the market introduction of Hejiya's siRNA drug pipeline [3]